Subarachnoid administration of hyperbaric 5% lignocaine solution has been associated with selflimited neurologic symptoms, with the first case reported in 1993 1 . Transient radicular irritation (TRI), as it has been described 2 , consists of moderate to severe aching pain located in the low lumbar and sacral dermatomes that begins less than 24 hours after subarachnoid block, persists for more than 24 hours and is self-limited. We report a case of TRI occurring after subarachnoid administration of hyperbaric 5% lignocaine in a patient undergoing incisional and inguinal herniorrhaphies.
CASE REPORT
A 68-year-old, 69 kg, ASA 3 male presented for surgical repair of a midline, subxyphoid, incisional hernia and a right inguinal hernia. His past medical history included hypertension, ischaemic heart disease, a remote history of cigarette smoking and anxiety with depressive symptoms. His current medications were atenolol and aspirin. He had no known drug allergies. Eighteen months previously the patient underwent coronary artery bypass surgery with induction complicated by difficult laryngoscopy. Only the epiglottis was visualized during direct laryngoscopy with a Macintosh 3 blade; the vocal cords were not identified and endotracheal intubation was facilitated by a gum elastic bougie. Recovery from the anaesthetic was uneventful.
Considering the patient's history of difficult intubation, subarachnoid block was chosen and supplemented with local anaesthetic infiltration at the superior margins of the incisional hernia. The patient was premedicated with midazolam 2 mg IV via an indwelling 18-gauge catheter. Subarachnoid injection was then performed after skin preparation with iodine skin antiseptic with the patient in a sitting position. Lignocaine 1% was infiltrated at the L3-4 interspace. The subarachnoid space was entered using a 24-gauge Sprotte® needle via a 20-gauge introducer. After free aspiration of 0.2 ml clear CSF, 80 mg of 5% lignocaine with 7.5% dextrose (Hyperbaric Xylocaine® Astra Pharmaceuticals) was injected and the patient placed supine. The level of the subarachnoid block was assessed using alcohol swabs. The patient demonstrated decreased temperature sensation to T6 on the left and T4 on the right. On several occasions during surgical preparation, the patient attempted to sit up and was reminded of the fact that a subarachnoid block was in place. Four episodes of mild hypotension to a systolic blood pressure of 100 mmHg were treated with Hartmann's solution 1500 ml IV, ephedrine 12 mg IV and metaraminol 1 mg IV. Flucloxacillin 1g was administered at the surgeon's request. Surgery was uneventfully performed with the patient in the supine position. Resolution of the motor block began in the recovery room 30 minutes after the procedure was completed. Full recovery of motor and sensory function was achieved within two hours of completion of the procedure.
Nine hours after resolution of the subarachnoid block, the patient described the onset of sharp, severe burning pain. This pain started in his mid-sacral region and radiated into his buttocks, lateral thighs, knees and proximal calves bilaterally. The pain increased while in the supine position, was maximal on rising from the bed and was alleviated by ambulating and with analgesics. Pressure or rubbing of the sacral region would also increase the level of discomfort. Inspection of the site of the subarachnoid block revealed no erythema or drainage, and the area was not tender to palpation. Approximately 16 hours after the onset of these symptoms the anaesthetist was con-tacted. The patient denied muscle weakness, sensory loss, bowel or bladder dysfunction. Neurologic examination was normal. In particular, there was no change in sensation to pinprick, touch or vibration and autonomic function was intact. A neurology consultation was requested to determine whether these symptoms were related solely to the subarachnoid block or whether they might be related to attempted patient movement during spinal anaesthesia and subsequent muscle strain. Imaging of the lumbar and sacral regions was performed with a CT and then an MRI. Both investigations were normal; specifically there was no identifiable abscess or haematoma. Over the following 48 hours the patient's pain was treated with pethidine IM, codeine p.o. and paracetamol p.o. with good relief. His pain continued to improve over the next four days with conservative management, and the patient was discharged five days postoperatively. The patient was pain-free at follow-up four weeks later.
DISCUSSION
In 1991, the initial case report concerning cauda equina syndrome related to spinal microcatheters was reported 3 . As the number of reported cases increased, some similarities became evident. These included the use of 5% lignocaine with 7.5% glucose, a higher than expected dose required to establish surgically appropriate block and total lignocaine dose exceeding 100 mg. Spinal microcatheters (28-gauge) were subsequently withdrawn from anaesthetic practice worldwide and reports of the cauda equina syndrome after spinal anaesthesia diminished. In 1993, the first case report documenting a transient, painful neuralgia following subarachnoid injection of hyperbaric lignocaine with surgery in the lithotomy position appeared 1 . Further case reports confirmed this observation and began to identify specific characteristics of this syndrome. Pinczower et al 4 cited five criteria common to nine cases they described in 1994. These were bilateral radicular-like leg pain with or without back pain, moderate or severe pain, onset of pain within 24 h of surgery, duration of pain longer than 24 h and no previous history of severe back or leg pain. Patient position during the procedure was not found to be significant. Of the 17 cases reviewed by these authors, nine conformed to these criteria and these nine patients had all received hyperbaric 5% lignocaine. This syndrome has been termed transient radicular irritation (TRI) 2 . The case reported here is consistent with prior reported cases of TRI in many respects.
Lignocaine has proved to be a safe and effective local anaesthetic for more than fifty years. With this track record, the recent reports of cauda equina syndrome and TRI are all the more worrying. While the exact incidence of TRI is difficult to determine, a non-randomized, prospective study by Tarkkila et al 2 reported an incidence of 10.2% in 600 patients. Schneider et al 1 documented four cases of TRI in 88 patients receiving subarachnoid hyperbaric 5% lignocaine. Even though the incidence of TRI is still uncertain, the aetiology has been more clearly elucidated.
In an attempt to identify the causative factors related to the cauda equina syndrome with spinal catheters, Lambert and Hurley 5 developed a spinal canal model to assess the spread of local anaesthetics. They were able to demonstrate pooling of hyperbaric 5% lignocaine in the distal portion of their prototype. Rigler and Drasner 6 produced a subarachnoid model that allowed sampling of the artificial cerebrospinal fluid at various levels. They were able to quantitate pooling of hyperbaric lignocaine and found that maldistribution occurred most commonly in caudally directed catheters where mixing of local anaesthetic with the cerebrospinal fluid was minimal. Rigler and Drasner suggested that pooling of lignocaine in the distal spinal canal was a contributing factor to the evolution of cauda equina syndrome. Additionally, a contributing factor to the occurrence of TRI may be related to streaming of local anaesthetic from the tip of the small-gauge spinal needles as demonstrated by Beardsley et al 7 . Mixing of local anaesthetic injected via small gauge needles may be adequate to avert the development of cauda equina syndrome but, maldistribution of hyperbaric local anaesthetic injected through side-port needles may be sufficient to result in radicular irritation. Indeed, the reported cases of TRI have occurred with the use of spinal needles of 24-gauge or smaller.
Furthermore, the hyperbaricity and hypertonicity of 5% lignocaine with 7.5% dextrose cannot be overlooked. Ready et al 8 demonstrated neurotoxicity of intrathecal lignocaine in a rabbit model, but only with concentrations in excess of those used clinically. However, Bainton et al 9 claimed that clinically used concentrations of lignocaine when directly applied to desheathed axons could irreversibly impair conduction. Drasner et al 10 expanded this work and were able to show that lignocaine 5% with dextrose 7.5% administered intrathecally in a rat model induced prolonged sensory deficits compared with hyperbaric tetracaine and bupivacaine. High concentrations of dextrose have not been shown to result in neurotoxicity 11 . However, the synergistic effect of 7.5% dextrose with 5% lignocaine has yet to be studied.
In conclusion, the use of hyperbaric 5% lignocaine has been associated with self-limited neurologic symptoms. The U.S. Food and Drug Administration currently recommends dilution of hyperbaric lignocaine with an equal volume of cerebrospinal fluid prior to subarachnoid injection. This recommendation is reflected in the new package insert of hyperbaric lignocaine. Moreover, de Jong 12 questions the continued use of hyperbaric lignocaine for subarachnoid block as it is presently dispensed. The end result remains the same; the use of hyperbaric lignocaine in a concentration of 5% for subarachnoid anaesthesia should be re-evaluated.
